

Other

Four additional Phase II studies with PN injections are sponsored by the National Cancer Institute (NCI) regarding primary malignant brain tumors, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, multiple myeloma, adenocarcinoma of the pancreas, and malignant melanoma.⁸

Five studies with oral formulations of A10 and AS2-1 (capsules) in breast, colon, lung, and prostate cancer are in process at the Burzynski Clinic. Two Phase II studies with AS2-1 capsules (one in hepatoma and another in colon cancer with liver metastases) are conducted at Kurume University School of Medicine, Japan under the supervision of the Japanese government.^{9,10} Two Phase II studies with AS2-1 capsules (one in HIV infection and another in autoimmune diseases) are conducted at the Burzynski Clinic.

Future Research Opportunities and Priorities

Only four FDA-supervised Phase II studies reached a final point, which allowed the conclusion that there is some antitumor activity in primary brain tumors. The priority is to complete the remaining Phase II studies. In addition, preclinical studies are conducted on a new generation of antineoplastons, which have an activity much higher than those currently used.

Office Applications

The illnesses that are most to least likely to be effectively treated based on the results of Phase II studies include the following: astrocytoma (low grade and anaplastic); mixed glioma; brain stem glioma; non-Hodgkin's lymphoma; oligodendroglioma; glioblastoma multiforme; adenocarcinoma of the pancreas; adenocarcinoma of the esophagus; adenocarcinoma of the prostate; carcinoma of unknown primary; rhabdoid tumor; PNET; and neuroblastoma.

Practical Applications

Antineoplastons are used in Phase II studies and under Special Exceptions (for patients who do not qualify for admission to Phase II studies). The physician or patient interested in this form of therapy should contact Burzynski Clinic at (281) 597-0111 or visit the web page at www.cancermed.com. The physician who would like to use antineoplastons will receive protocol and an informational brochure and will be required to fill out FDA Form 1572. There are no charges for pharmaceutical formulations of A10 and AS2-1, but there is a charge for services and equipment (such as the pump). The patient may receive the treatment under the care of a local physician or at Burzynski Clinic. After the initial review of the medical records, patients are then informed if they are qualified for admission to a clinical study. Such patients then are invited to Burzynski Clinic in Houston for a consultation. After 2 weeks of treatment at Burzynski Clinic they may return home and continue